Melvin Fox

987 total citations
18 papers, 700 citations indexed

About

Melvin Fox is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Melvin Fox has authored 18 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Melvin Fox's work include Cell Adhesion Molecules Research (5 papers), Immunotherapy and Immune Responses (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Melvin Fox is often cited by papers focused on Cell Adhesion Molecules Research (5 papers), Immunotherapy and Immune Responses (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Melvin Fox collaborates with scholars based in United States and Germany. Melvin Fox's co-authors include Debra T. Chao, Gary C. Starling, Nicole A. Belmar, Audie Rice, Michael Robbins, Balaji Balasa, Robert B. DuBridge, Pauline Wales, Vinay Bhaskar and Vanitha Ramakrishnan and has published in prestigious journals such as The Journal of Immunology, Cancer Research and British Journal of Cancer.

In The Last Decade

Melvin Fox

17 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melvin Fox United States 11 318 266 217 147 95 18 700
Sylvie Galiègue‐Zouitina France 17 749 2.4× 246 0.9× 151 0.7× 284 1.9× 102 1.1× 41 1.3k
R E Leake United Kingdom 17 321 1.0× 247 0.9× 206 0.9× 67 0.5× 41 0.4× 34 796
Haiyun Cheng United States 9 568 1.8× 472 1.8× 193 0.9× 123 0.8× 73 0.8× 12 944
Denise Howe United Kingdom 12 845 2.7× 575 2.2× 195 0.9× 154 1.0× 36 0.4× 21 1.2k
Bruno Morolli Netherlands 13 521 1.6× 125 0.5× 206 0.9× 64 0.4× 53 0.6× 21 762
Beatriz Albella Spain 14 318 1.0× 168 0.6× 107 0.5× 255 1.7× 256 2.7× 31 803
Dariush Farahi Far France 12 522 1.6× 322 1.2× 121 0.6× 167 1.1× 85 0.9× 16 811
Heidi Y. Shi United States 14 371 1.2× 192 0.7× 289 1.3× 71 0.5× 28 0.3× 19 685
Peter H. Clingen United Kingdom 13 690 2.2× 223 0.8× 245 1.1× 88 0.6× 19 0.2× 17 990
LJ Fairbairn United Kingdom 17 566 1.8× 295 1.1× 107 0.5× 257 1.7× 207 2.2× 32 1.0k

Countries citing papers authored by Melvin Fox

Since Specialization
Citations

This map shows the geographic impact of Melvin Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Fox more than expected).

Fields of papers citing papers by Melvin Fox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Fox. The network helps show where Melvin Fox may publish in the future.

Co-authorship network of co-authors of Melvin Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Fox. A scholar is included among the top collaborators of Melvin Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Fox. Melvin Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Thakur, Archana, Melvin Fox, Enrico L. DiGiammarino, et al.. (2020). Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity. Molecular Cancer Therapeutics. 19(4). 1040–1051. 30 indexed citations
2.
Purcell, James W., Jonathan A. Hickson, Melvin Fox, et al.. (2018). LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates. Cancer Research. 78(14). 4059–4072. 136 indexed citations
3.
Harding, Fiona, Nicole A. Belmar, C.M. Forsyth, et al.. (2018). Blockade of CD25 reduces regulatory T cell expansion and some manifestations of IL-2 mediated toxicity but does not improve anti-tumor efficacy in animal models of IL-2 immunotherapy. The Journal of Immunology. 200(Supplement_1). 57.3–57.3. 1 indexed citations
4.
Ye, Shiming, Melvin Fox, Nicole A. Belmar, et al.. (2017). Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. Journal of Immunology Research. 2017. 1–14. 12 indexed citations
5.
Belmar, Nicole A., Sarah Chan, Melvin Fox, et al.. (2017). Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice. The Journal of Immunology. 198(11). 4502–4512. 2 indexed citations
6.
Hickson, Jonathan A., Melvin Fox, David Chao, et al.. (2016). ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment. European Journal of Cancer. 69. S10–S10. 1 indexed citations
7.
Purcell, James W., Melvin Fox, Peter Lambert, et al.. (2014). Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Frontiers in Immunology. 4. 505–505. 12 indexed citations
8.
Balasa, Balaji, Nicole A. Belmar, Melvin Fox, et al.. (2014). Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunology Immunotherapy. 64(1). 61–73. 123 indexed citations
9.
Ye, Shiming, Melvin Fox, Nicole A. Belmar, et al.. (2012). Abstract 2722: Active recruitment of immune effector cells mediates in vivo tumor growth inhibition by enavatuzumab, an antibody to human TWEAK receptor. Cancer Research. 72(8_Supplement). 2722–2722. 1 indexed citations
10.
Bhaskar, Vinay, Melvin Fox, Melanie Wong, et al.. (2007). Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Investigational New Drugs. 26(1). 7–12. 44 indexed citations
11.
Bhaskar, Vinay, Dong Zhang, Melvin Fox, et al.. (2007). A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. Journal of Translational Medicine. 5(1). 61–61. 66 indexed citations
12.
Bhaskar, Vinay, et al.. (2004). M200, a Chimeric Antibody Against Integrin alpha5 beta1, Inhibits Cancer Cell Growth In Vitro. Journal of Immunotherapy. 27(6). S9–S9.
13.
Fox, Melvin. (1984). Molecular Biology of Mutagens and Carcinogens. British Journal of Cancer. 49(6). 817–817. 31 indexed citations
14.
Fox, Melvin. (1981). Molecular and Cellular Aspects of Carcinogen Screening Tests. British Journal of Cancer. 43(2). 250–250. 128 indexed citations
15.
Fox, Melvin. (1978). Carcinogenicity Testing: principles and Problems. British Journal of Cancer. 38(4). 565–566. 5 indexed citations
16.
Fox, Melvin & David C. Scott. (1977). Human Tumours in Short Term Culture: techniques and Clinical Applications. British Journal of Cancer. 35(3). 386–387. 6 indexed citations
17.
Hendry, J H, et al.. (1976). Biology of Radiation Carcinogenesis. British Journal of Cancer. 34(5). 577–579. 30 indexed citations
18.
Fox, Melvin. (1976). Screening Tests in Chemical Carcinogenesis. British Journal of Cancer. 34(5). 576–577. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvie Galiègue‐Zouitina Breakdown of academic impact, for papers by R E Leake Breakdown of academic impact, for papers by Haiyun Cheng Breakdown of academic impact, for papers by Denise Howe Breakdown of academic impact, for papers by Bruno Morolli Breakdown of academic impact, for papers by Beatriz Albella Breakdown of academic impact, for papers by Dariush Farahi Far Breakdown of academic impact, for papers by Heidi Y. Shi Breakdown of academic impact, for papers by Peter H. Clingen Breakdown of academic impact, for papers by LJ Fairbairn
Rankless by CCL
2026